Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas

NCT04617002 is registered in ClinicalTrials.gov with Jazz Pharmaceuticals as lead sponsor.

NCT NCT04617002
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04617002 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas
Lead sponsor
Jazz Pharmaceuticals
Phase
Expanded access
Overall status
Approved for marketing
Start date
Not reported
Completion date
Not reported
Enrollment
Not reported
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

glioma, h3 k27m